Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

a Toshe_O Immunocore Holdings plc (NASDAQ:IMCR) is a commercial-stage biotechnology company that develops immunotherapies for cancer, infectious diseases, and autoimmune conditions. Its leading commercial product, KIMMTRAK, is a bispecific protein for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. KIMMTRAK is currently approved in 38 countries, including the US, EU, Canada, Australia, and the UK, showing a promising revenue trajectory in 2024. Additionally, IMCR has a diverse pi ...